About this trial
This study aims to evaluate the correlation between stroke volume measurements obtained by transthoracic echocardiography and bioreactance-based noninvasive cardiac output monitoring. The primary objective is to assess the level of agreement between these two modalities in critically ill patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Clinical diagnosis of shock as determined by the treating ICU physician (e.g., hypotension requiring vasopressors or evidence of end-organ hypoperfusion)
Able to obtain informed consent from the patient or a legally authorized representative
Enrollment within 24 hours of ICU admission
Disqualifiers
Pregnancy
Known severe aortic valve disease or dynamic left ventricular outflow tract obstruction
Morbid obesity (BMI > 40) that precludes accurate echocardiographic imaging Presence of cardiac arrhythmias (e.g., atrial fibrillation with rapid ventricular response) affecting stroke volume measurements
Implanted cardiac assist devices (e.g., LVAD, pacemaker dependency)
Trial population
Adult patients admitted to the intensive care unit (ICU) with clinical signs of shock, including hypotension and/or evidence of end-organ hypoperfusion, who are able to provide informed consent or have a legally authorized representative available.
Trial design
Cohort
Prospective
Treatments tested in this trial
Cheetah NICOM
DeviceBioreactance-based noninvasive cardiac output monitoring device used to measure stroke volume before and after passive leg raising. Used solely for observational measurement. No therapeutic intervention is performed.
Treatment groups
Trial outcomes
Primary outcomes
Correlation Between Stroke Volume Measurements by Echocardiography and Bioreactance Monitoring
Pearson correlation coefficient between stroke volume measurements obtained using transthoracic echocardiography and those obtained using bioreactance-based monitoring (Cheetah NICOM) in response to passive leg raising.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.